article thumbnail

Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold

Xconomy

A Phase 1 trial testing a Poseida Therapeutics cell therapy in men with prostate cancer is on hold after a patient enrolled in the study died of liver failure nearly three weeks after receiving the treatment.

Study 107
article thumbnail

Study: Users Not Willing To Pay To Use Twitter, Other Online Services

socalTECH

A study released Friday by the Center for the Digital Future, at the USC Annenberg School of Communications, finds that zero percent of Twitter users polled in the study would pay for Twitter. The findings came as part of the Center's 2010 Digital Future Project, a long term study of Internet users and non-users.

Study 170
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target

Xconomy

In study results published Wednesday, the presence of the specific protein fragment that Epic (not to be confused with Verona, WI-based EHR software maker Epic Systems) tests for in circulating tumor cells predicted a shorter median length of survival for men whose disease has spread.

Study 98
article thumbnail

Study: Reflexion Health Virtual Therapy System Reduces Rehab Costs

Xconomy

The study, which evaluated Reflexion’s system for patients after total knee replacement surgery, was conducted in conjunction with the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine.

Study 83
article thumbnail

Company Offering $10K for a 30 Day Phone Detox, Apply Now

Tech.Co

Siggi’s Dairy Sets Digital Detox Challenge “We're introducing a new kind of “Dry January” this year,” Siggi’s explains in a recent blog post. So, if you think you can last for the whole month without your phone if $10,000 is put on the line, here’s an outline of the competition and how to enter.

Company 228
article thumbnail

Viking Liver Drug Shows Promise for NASH, Shares Soar on Study Data

Xconomy

Viking Therapeutics released preliminary results from a Phase 2 study suggesting its experimental drug might impact some of the disease’s many dangerous effects on the liver.

Study 76
article thumbnail

Roche Challenger to Biogen’s SMA Drug Succeeds in Pivotal Study

Xconomy

A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder. The Basel, Switzerland-based company plans to present full data from the study at a future medical conference.

Study 49